JLK

JLK Current Assets

The Current Assets of JLK (322510.KQ) as of Nov 3, 2026 is 19.30 M KRW. In the previous year, Current Assets was 48.36 B KRW — a change of -99.96% (lower).

Current Assets

19.30 MKRW

YoY

-99.96%

Last updated:

Current Assets of JLK is 2025 19.30 M KRW. Current Assets of JLK was 2024 48.36 B KRW. It decreases by -99.96% lower compared to the previous year.

The JLK Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
7.43 B KRW
Jan 1, 2019
36.28 B KRW
Jan 1, 2020
18.80 B KRW
Jan 1, 2021
11.71 B KRW
Jan 1, 2022
8.79 B KRW
Jan 1, 2023
6.60 B KRW
Jan 1, 2024
48.36 B KRW
Jan 1, 2025
19.30 M KRW
The JLK Current Assets history
YEARCurrent AssetsYoY
19.30 MKRW-99.96%
48.36 BKRW+632.72%
6.60 BKRW-24.89%
8.79 BKRW-24.95%
11.71 BKRW-37.71%
18.80 BKRW-48.18%
36.28 BKRW+388.47%
7.43 BKRW+86.99%
3.97 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JLK Stock analysis

What does JLK do? JLK, Inc. generates revenue through AI medical analysis solutions, AI industry and security analysis solutions, and AI medical diagnostic platforms. The company's products include AI medical systems, AI quantitative analysis platforms, and AI remote platforms, which are sold to healthcare providers and medical institutions. The primary customer segments are hospitals and clinics seeking advanced diagnostic tools for brain disease detection. Revenue streams are derived from software licensing and subscription services for these AI-driven diagnostic systems. JLK, Inc. focuses on developing AI-based data-driven diagnostic systems specifically for brain disease detection. The company's AI medical diagnostic platforms are designed to provide accurate and efficient analysis for medical professionals. These platforms are part of the broader suite of AI medical analysis solutions that include AI quantitative analysis and AI remote platforms. The firm's target market includes healthcare facilities requiring cutting-edge technology for neurological diagnostics. The company's software products, such as AI medical systems and AI quantitative analysis platforms, are marketed to healthcare institutions for integration into their diagnostic workflows. Revenue is primarily generated through licensing agreements and recurring subscription fees for access to the AI-driven diagnostic tools. These solutions are positioned as essential for modern healthcare providers aiming to enhance diagnostic accuracy and patient outcomes in brain disease detection. JLK is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JLK stock

Current Assets of JLK is 19.30 M KRW in 2025.

Current Assets of JLK changed from 48.36 B KRW to 19.30 M KRW, representing a -99.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets JLK since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's JLK historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — JLK

All Key Metrics — JLK